Lilly finalizes Zyprexa settlement with insurers; Now buying, Gruenenthal eyes Brazilian deals;

 @FiercePharma: Our take on the Novartis job cuts: One thing's sure, no reps will strike in protest ($NVS). Article | Follow @FiercePharma

> Eli Lilly ($LLY) won court approval of a $4.5 million settlement with 6 payers that claimed that the company's Zyprexa marketing caused them to overpay for the drug. Article

> Germany's Gruenenthal has earmarked $1 billion for acquisitions to expand in Latin America, and it's already shopping for deals in Brazil, CEO Harald Stock said. Story

> Perrigo plans to add 45 new store-brand, over-the-counter drugs to its stable in 2012, augmenting sales by $190 million, CEO Joseph Papa told Bloomberg. More

> Shire ($SHPGY) inked a deal with generics maker Prasco Laboratories on an authorized copy of its Carbatrol anti-seizure and nerve pain medicine. News

> CVS Caremark ($CVS) agreed to pay $5 million to settle claims that it misrepresented Medicare drug prices, closing a two-year Federal Trade Commission probe. Story

> Canada-based drug delivery specialist Kedem Pharmaceuticals ($KDMP) moved its headquarters to Mesa, AZ, and plans a new R&D lab in Scottsdale. Article

> New Jersey Gov. Chris Christie has until Tuesday to decide whether to sign or veto a repeal of the so-called "Botox Tax," the first state levy on cosmetic procedures in the U.S. News

> India's Ind-Swift has signed on to market Roche's ($RHHBY) heart-attack detection kits in India in a deal that could lead to more marketing collaborations with the Swiss company. Report

> Sri Lanka's PC Pharma is planning a stock listing to help fund acquisitions and a new manufacturing plant. More

Biotech News

@FierceBiotech: Will 2012 see a big spike in biotech buyouts? Short answer: "You can never have enough pipeline." More | Follow @FierceBiotech

@JohnCFierce: Will biotech buyouts be the focus in Europe, following end of the megadeal and a round of stock buybacks? Likely. Story | Follow @JohnCFierce

@RyanMFierce: Onyx Pharma's Matt Fust didn't say the company's for sale, but that it'd be an attractive takeover target. That sounds like selling to me. | Follow @RyanMFierce

@FierceMedDev: Device company Launch Medical investing $4.8 million in Bartlett expansion-- via @MBJMemphis. Article | Follow @FierceMedDev

> PhRMA touts pediatric pipeline as it recruits lawmakers on legislation. Story

> Onyx Pharma CFO plugs cancer pipeline amid rumored sales process. Article

And Finally... Can't break a bad habit? Blame dopamine neurons in the brain's basal ganglia, researchers say. Release

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…